Form 4 for CADL Candel Therapeutics, Inc.
Accepted 2025-03-20 00:00:00 ET · period of report 2025-03-18 · accession 0000950170-25-042728 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2025-03-20 | 2025-03-18 | CADL | Nichols William Garrett | Chief Medical Off | M - OptEx | $1.90 | +18.5K | 97.8K | +23% | +$35.1K |
| DT | 2025-03-20 | 2025-03-18 | CADL | Nichols William Garrett | Chief Medical Off | S - Sale+OE | $8.76 | -45.3K | 52.5K | -46% | -$397.0K |
| DMT | 2025-03-20 | 2025-03-18 | CADL | Nichols William Garrett | Chief Medical Off | M - OptEx | $0.00 | -18.5K | 31.1K | -37% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-18 | M | A | 4,584 | $3.75 | 83,904 | D | — | — | |
| 2 | Common | Common Stock | 2025-03-18 | M | A | 13,905 | $1.29 | 97,809 | D | — | — | |
| 3 | Common | Common Stock | 2025-03-18 | S | D | 45,316 | $8.76 | 52,493 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.36 to $9.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein. |
| 4 | Derivative | Stock Option (Right to Buy) | 2025-03-18 | M | D | 4,584 | $0.00 | 195,416 | D | $3.75 · — to 2032-09-12 | 4,584 Common Stock | (F3) The first 100,000 shares underlying this option shall vest as follows: 25% shall vest and become exercisable on September 12, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. The remaining 100,000 shares underlying this option shall vest as follows: 25% shall vest and become exercisable on the first anniversary of the date in which the Reporting Person converts to a full-time employee, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| 5 | Derivative | Stock Option (Right to Buy) | 2025-03-18 | M | D | 13,905 | $0.00 | 31,095 | D | $1.29 · — to 2033-04-28 | 13,905 Common Stock | (F4) This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date. |